KVUE stock price: Kenvue soars 19% today, Kimberly-Clark deal offers a win after Trump Tylenol drama
The announcement comes just weeks after President Trump publicly spread debunked claims that Tylenol consumption is linked to autism.
It’s been a tough few weeks for the consumer health company Kenvue, after President Trump publicly spread unproven claims about Tylenol, one of its core subsidiary brands. Today, though, it seems like there might finally be some good news for Kenvue.
What did you think of this news? Leave a comment below and/or share it on your social media. This way, we can inform more people about the hottest things in technology, science, innovation, and gaming!
This news was originally published in:
Original source
